Senkardes, Sevil published the artcileSynthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors, Product Details of C8H4ClF3O, the main research area is prostate breast cancer fibroblast cell COX2 inhibitor sulfonyl hydrazone; Anticancer activity; Apoptosis; Cyclooxygenase; Molecular docking; Sulfonylhydrazones.
In trying to develop new anticancer agents, a series of sulfonylhydrazones were synthesized. All synthesized compounds were checked for identity and purity using elemental anal., TLC and HPLC and were characterized by their m.ps., FT-IR and NMR spectral data and evaluated for their cytotoxic activity against prostate cancer (PC3), breast cancer (MCF-7) and L929 mouse fibroblast cell lines. Among them, N’-[(2-chloro-3-methoxyphenyl)methylidene]-4-methylbenzenesulfonohydrazide (3k) showed the potent anticancer activity against both cancer cells with good selectivity. Further investigation confirmed that 3k displayed morphol. alterations in PC3 and MCF-7 cells and promoted apoptosis through down-regulation of the Bcl-2 and upregulation of Bax expression. Addnl., compound 3k was identified as the most potent COX-2 inhibitor (91% inhibition) beside lower COX-1 inhibition. Mol. docking of the tested compounds represented important binding modes which may be responsible for their anticancer activity via inhibition of the COX-2 enzyme. Overall, the lead compound 3k deserves further development as a potential anticancer agent.
Molecular Diversity published new progress about Antitumor agents. 93118-03-7 belongs to class chlorides-buliding-blocks, name is 2-Chloro-3-(trifluoromethyl)benzaldehyde, and the molecular formula is C8H4ClF3O, Product Details of C8H4ClF3O.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics